Loading stock data…
$72.57+0.78 (+1.09%)
10x Genomics, Inc.
10x Genomics, Inc. in the Healthcare sector is trading at $72.55 with a market capitalization of $8.5B. Wall Street consensus targets $75.67 (15 analysts), implying a +4.3% move over the next 12 months. The stock is currently 29% below its 52-week high of $102.81, remaining 94.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $151.04M↑ | $150.84M↓ | $166.03M↑ | $149.00M↓ | $172.91M |
| Gross Profit | $112.50M↑ | $106.18M↓ | $113.05M↑ | $100.31M↓ | $125.08M |
| Operating Income | -$22.95M↓ | -$17.05M↑ | -$19.54M↑ | -$32.24M↓ | -$10.57M |
| Net Income | -$17.93M↓ | -$13.47M↑ | -$16.25M↑ | -$27.47M↓ | $34.54M |
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chr...